Pennsylvania, USA-based clinical-stage biotech SFA Therapeutics has appointed of Dr Stefan Weiss as chief medical officer in a move to strengthen its management team.
Dr Weiss is a physician-scientist and entrepreneur with 25 years of experience in the healthcare and life sciences industries. Most recently, Dr Weiss was the managing director of dermatology at OM1, a company focused on health care data analytics and artificial intelligence.
In this position, he was responsible for deepening OM1's clinical focus and expertise around Immunology. He provided guidance on the scientific standards and clinical relevance of real-world data offerings across immunologic diseases. In addition, he oversaw the development of prospective studies to collect real-world evidence, including the ClinPro Derm Protocol.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze